Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody-Drug Conjugates.

Lee BC, Chalouni C, Doll S, Nalle SC, Darwish M, Tsai SP, Kozak KR, Del-Rosario G, Yu SF, Erickson H, Vandlen R.

Bioconjug Chem. 2018 Jul 18;29(7):2468-2477. doi: 10.1021/acs.bioconjchem.8b00362. Epub 2018 Jun 13.

PMID:
29856915
2.

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.

Dragovich PS, Blake RA, Chen C, Chen J, Chuh J, den Besten W, Fan F, Fourie A, Hartman SJ, He C, He J, Ingalla ER, Kozak KR, Leong SR, Lu J, Ma Y, Meng L, Nannini M, Oeh J, Ohri R, Lewis Phillips G, Pillow TH, Rowntree RK, Sampath D, Vandlen R, Vollmar B, Wai J, Wertz IE, Xu K, Xu Z, Zhang D.

Chemistry. 2018 Apr 3;24(19):4830-4834. doi: 10.1002/chem.201800859. Epub 2018 Mar 25.

PMID:
29493023
3.

Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.

Su D, Kozak KR, Sadowsky J, Yu SF, Fourie-O'Donohue A, Nelson C, Vandlen R, Ohri R, Liu L, Ng C, He J, Davis H, Lau J, Del Rosario G, Cosino E, Cruz-Chuh JD, Ma Y, Zhang D, Darwish M, Cai W, Chen C, Zhou H, Lu J, Liu Y, Kaur S, Xu K, Pillow TH.

Bioconjug Chem. 2018 Apr 18;29(4):1155-1167. doi: 10.1021/acs.bioconjchem.7b00785. Epub 2018 Mar 13.

PMID:
29481745
4.

High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.

Ohri R, Bhakta S, Fourie-O'Donohue A, Dela Cruz-Chuh J, Tsai SP, Cook R, Wei B, Ng C, Wong AW, Bos AB, Farahi F, Bhakta J, Pillow TH, Raab H, Vandlen R, Polakis P, Liu Y, Erickson H, Junutula JR, Kozak KR.

Bioconjug Chem. 2018 Feb 21;29(2):473-485. doi: 10.1021/acs.bioconjchem.7b00791. Epub 2018 Feb 9.

PMID:
29425028
5.

Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads.

Zhang D, Le H, Cruz-Chuh JD, Bobba S, Guo J, Staben L, Zhang C, Ma Y, Kozak KR, Lewis Phillips GD, Vollmar BS, Sadowsky JD, Vandlen R, Wei B, Su D, Fan P, Dragovich PS, Khojasteh SC, Hop CECA, Pillow TH.

Bioconjug Chem. 2018 Feb 21;29(2):267-274. doi: 10.1021/acs.bioconjchem.7b00576. Epub 2018 Feb 7.

PMID:
29369629
6.

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, Yu SF, Ng C, Guo J, Liu Y, Fourie-O'Donohue A, Go M, Linghu X, Segraves NL, Wang T, Chen J, Wei B, Phillips GD, Xu K, Kozak KR, Mariathasan S, Flygare JA, Pillow TH.

Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635. Epub 2016 Oct 17.

PMID:
27874860
7.

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus.

Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S.

Nature. 2015 Nov 19;527(7578):323-8. doi: 10.1038/nature16057. Epub 2015 Nov 4.

PMID:
26536114
8.

Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.

Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C.

Protein Sci. 2015 Sep;24(9):1440-50. doi: 10.1002/pro.2729. Epub 2015 Aug 18.

9.

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates.

Cuellar TL, Barnes D, Nelson C, Tanguay J, Yu SF, Wen X, Scales SJ, Gesch J, Davis D, van Brabant Smith A, Leake D, Vandlen R, Siebel CW.

Nucleic Acids Res. 2015 Jan;43(2):1189-203. doi: 10.1093/nar/gku1362. Epub 2014 Dec 30.

10.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
11.

Real-time immuno-polymerase chain reaction in a 384-well format: detection of vascular endothelial growth factor and epidermal growth factor-like domain 7.

Zhang J, Vernes JM, Ni J, Nelson C, Wong A, Chen ST, Asundi A, Vandlen R, Meng YG.

Anal Biochem. 2014 Oct 15;463:61-6. doi: 10.1016/j.ab.2014.06.024. Epub 2014 Jul 8.

PMID:
25013989
12.

Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins.

Hazenbos WL, Kajihara KK, Vandlen R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, Sai T, Sebrell A, Khalfin Y, Oh A, Koth C, Lin SJ, Lee BC, Strandh M, Koefoed K, Andersen PS, Spits H, Brown EJ, Tan MW, Mariathasan S.

PLoS Pathog. 2013;9(10):e1003653. doi: 10.1371/journal.ppat.1003653. Epub 2013 Oct 10.

13.

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.

Cohn L, Chatterjee B, Esselborn F, Smed-Sörensen A, Nakamura N, Chalouni C, Lee BC, Vandlen R, Keler T, Lauer P, Brockstedt D, Mellman I, Delamarre L.

J Exp Med. 2013 May 6;210(5):1049-63. doi: 10.1084/jem.20121251. Epub 2013 Apr 8.

14.

Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.

Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC, Eigenbrot C.

J Mol Biol. 2013 Apr 26;425(8):1330-9. doi: 10.1016/j.jmb.2013.01.024. Epub 2013 Jan 25.

PMID:
23357170
15.

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R.

PLoS One. 2012;7(12):e51817. doi: 10.1371/journal.pone.0051817. Epub 2012 Dec 20.

16.

Real-time quantification of antibody-short interfering RNA conjugate in serum by antigen capture reverse transcription-polymerase chain reaction.

Tan M, Vernes JM, Chan J, Cuellar TL, Asundi A, Nelson C, Yip V, Shen B, Vandlen R, Siebel C, Meng YG.

Anal Biochem. 2012 Nov 15;430(2):171-8. doi: 10.1016/j.ab.2012.08.018. Epub 2012 Aug 26. Review.

PMID:
22929697
17.

Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.

Chatterjee B, Smed-Sörensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, Widger J, Keler T, Delamarre L, Mellman I.

Blood. 2012 Sep 6;120(10):2011-20. doi: 10.1182/blood-2012-01-402370. Epub 2012 Jul 12.

18.

Translation levels control multi-spanning membrane protein expression.

Kim HS, Ernst JA, Brown C, Bostrom J, Fuh G, Lee CV, Huang A, Vandlen RL, Yansura DG.

PLoS One. 2012;7(4):e35844. doi: 10.1371/journal.pone.0035844. Epub 2012 Apr 26.

19.

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B.

J Virol. 2012 Jul;86(13):7444-7. doi: 10.1128/JVI.00467-12. Epub 2012 Apr 24.

20.

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR.

Nat Biotechnol. 2012 Jan 22;30(2):184-9. doi: 10.1038/nbt.2108.

PMID:
22267010
21.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

22.

Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, Iyer S, Shields RL, Chiang N, Bauer MC, Wadley D, Roose-Girma M, Vandlen R, Yansura DG, Wu Y, Wu LC.

J Biol Chem. 2010 Jul 2;285(27):20850-9. doi: 10.1074/jbc.M110.113910. Epub 2010 May 5.

23.

Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET.

Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams SP, Marik J.

Nucl Med Biol. 2010 Apr;37(3):289-97. doi: 10.1016/j.nucmedbio.2009.11.010. Epub 2010 Feb 10.

PMID:
20346868
24.

Spatial control of EGF receptor activation by reversible dimerization on living cells.

Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I.

Nature. 2010 Apr 1;464(7289):783-7. doi: 10.1038/nature08827. Epub 2010 Mar 7.

PMID:
20208517
25.

A modular platform for the rapid site-specific radiolabeling of proteins with 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2.

Gill HS, Tinianow JN, Ogasawara A, Flores JE, Vanderbilt AN, Raab H, Scheer JM, Vandlen R, Williams SP, Marik J.

J Med Chem. 2009 Oct 8;52(19):5816-25. doi: 10.1021/jm900420c.

PMID:
19736996
26.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

27.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
28.

Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A.

Bioconjug Chem. 2008 Aug;19(8):1673-83. doi: 10.1021/bc800059t. Epub 2008 Jul 19.

PMID:
18637680
29.

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs.

Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, Scheller RH, Lowman HB.

J Immunol Methods. 2008 Mar 20;332(1-2):41-52. doi: 10.1016/j.jim.2007.12.011. Epub 2008 Jan 14.

PMID:
18230399
30.

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.

Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C, Hongo JA, Gogineni A, Cole MJ, Vandlen R, Stephan JP, Young J, Chang W, Scales SJ, Ross S, Eaton D, Ebens A.

Blood. 2007 Jul 15;110(2):616-23. Epub 2007 Mar 20.

31.

Cutting edge: novel human dendritic cell- and monocyte-attracting chemokine-like protein identified by fold recognition methods.

Pisabarro MT, Leung B, Kwong M, Corpuz R, Frantz GD, Chiang N, Vandlen R, Diehl LJ, Skelton N, Kim HS, Eaton D, Schmidt KN.

J Immunol. 2006 Feb 15;176(4):2069-73.

32.

Isolation and characterization of the B-cell marker CD20.

Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL.

Biochemistry. 2005 Nov 22;44(46):15150-8.

PMID:
16285718
33.

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA.

Endocrinology. 2004 Jun;145(6):2594-603. Epub 2004 Feb 19.

PMID:
14976145
34.

The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.

Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A.

Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15. Erratum in: Genome Res. 2003 Dec;13(12):2759.

35.

Novel non-isotopic method for the localization of receptors in tissue sections.

Desnoyers L, Simonette RA, Vandlen RL, Fendly BM.

J Histochem Cytochem. 2001 Dec;49(12):1509-18.

PMID:
11724898
36.

IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.

Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ, Vandlen R.

Cytokine. 2001 Jan 7;13(1):1-7.

PMID:
11145836
37.

IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1.

Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL.

J Biol Chem. 2001 Jan 12;276(2):1660-4.

38.

Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin.

Chen L, Hoeger C, Rivier J, Fitzpatrick VD, Vandlen RL, Tashjian AH Jr.

Biochem Biophys Res Commun. 1999 May 19;258(3):689-94.

PMID:
10329447
39.

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.

Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX.

FEBS Lett. 1998 Jul 10;431(1):102-6.

40.

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.

Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E Jr, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, Phillips HS.

J Neurosci. 1998 Jul 1;18(13):4929-37.

41.

Persephin, a novel neurotrophic factor related to GDNF and neurturin.

Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Johnson EM Jr, et al.

Neuron. 1998 Feb;20(2):245-53.

42.

Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells.

Chen L, Fitzpatrick VD, Vandlen RL, Tashjian AH Jr.

J Biol Chem. 1997 Jul 25;272(30):18666-72.

43.

A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Klein RD, Sherman D, Ho WH, Stone D, Bennett GL, Moffat B, Vandlen R, Simmons L, Gu Q, Hongo JA, Devaux B, Poulsen K, Armanini M, Nozaki C, Asai N, Goddard A, Phillips H, Henderson CE, Takahashi M, Rosenthal A.

Nature. 1997 Jun 12;387(6634):717-21. Erratum in: Nature 1998 Mar 12;392(6672):210.

PMID:
9192898
44.

Glycerophosphorylethanolamine (GPEA) identified as an hepatocyte growth stimulator in liver extracts.

Nelson C, Moffat B, Jacobsen N, Henzel WJ, Stults JT, King KL, McMurtrey A, Vandlen R, Spencer SA.

Exp Cell Res. 1996 Nov 25;229(1):20-6.

PMID:
8940245
45.

Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2.

Liapakis G, Fitzpatrick D, Hoeger C, Rivier J, Vandlen R, Reisine T.

J Biol Chem. 1996 Aug 23;271(34):20331-9.

46.

Characterization of a multicomponent receptor for GDNF.

Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A.

Nature. 1996 Jul 4;382(6586):80-3.

PMID:
8657309
47.

High-level expression and characterization of a purified 142-residue polypeptide of the prion protein.

Mehlhorn I, Groth D, Stöckel J, Moffat B, Reilly D, Yansura D, Willett WS, Baldwin M, Fletterick R, Cohen FE, Vandlen R, Henner D, Prusiner SB.

Biochemistry. 1996 Apr 30;35(17):5528-37.

PMID:
8611544
48.

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.

Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N.

J Biol Chem. 1996 Mar 29;271(13):7788-95.

49.

Decreased food intake does not completely account for adiposity reduction after ob protein infusion.

Levin N, Nelson C, Gurney A, Vandlen R, de Sauvage F.

Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1726-30.

50.

The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation.

Walter DH, Hink U, Asahara T, Van Belle E, Horowitz J, Tsurumi Y, Vandlen R, Heinsohn H, Keyt B, Ferrara N, Symes JF, Isner JM.

Lab Invest. 1996 Feb;74(2):546-56.

PMID:
8780172

Supplemental Content

Loading ...
Support Center